Roche to start new Elevidys study following setback in Europe
BioPharma Dive
The Swiss drugmaker, which owns rights to the Duchenne gene therapy outside the U.S., hopes the trial will yield additional approvals in Europe and elsewhere.
pharminent
April 16, 2026 (Last updated: April 16, 2026)
BioPharma Dive
The Swiss drugmaker, which owns rights to the Duchenne gene therapy outside the U.S., hopes the trial will yield additional approvals in Europe and elsewhere.